A novel prognostic model has been developed to help determine the timing of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory multiple myeloma (MM). The model aims to predict early relapse to CAR-T therapy, which is associated with increased mortality risk. The model, called Myeloma CAR-T Relapse (MyCARe), considers factors such as extramedullary disease, lenalidomide refractoriness, high-risk cytogenetics, and high ferritin levels. The model effectively predicts the 5-month relapse rate and can help optimize patient selection for CAR-T therapy in this challenging population. The study included data from 269 patients and showed comparable outcomes between European and American cohorts.
Source link
Novel Model Effectively Predicts Early Relapse After CAR-T Therapy in Myeloma
